Skip to main content
Premium Trial:

Request an Annual Quote

Genaissance and Prometheus Expand License, Start Collaboration

NEW YORK, May 16 - Genaissance Pharmaceuticals and Prometheus Laboratories have expanded a licensing agreement and plan to collaborate to identify genetic markers, the companies said today.

 

Prometheus, which licenses a thiopurine S-methyltransferase (TPMT) genetic test from Genaissance, will now be able to use it more broadly. The test assesses a patient's ability to metabolize thiopurine drugs, which are commonly used to treat autoimmune and inflammatory diseases. Genaissance acquired the rights to this test through its purchase of the assets of DNA Sciences.

 

Prometheus paid Genaissance an upfront fee for the license expansion and will make further payments based on net sales.

 

In addition, Genaissance and Prometheus plan to collaborate to identify genetic markers that predict patient responses to therapies used to treat gastrointestinal tract diseases as well as autoimmune and inflammatory diseases. Prometheus focuses on these disease areas.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.